New medicine may greatly reduce ARDS morbidity and mortality

Eighty percent is a significant number, especially when you're referring to an 80 percent lower death rate.  That's what reserchers discovered happened when they trialed patients with Acute Respiratory Distress Syndrome (ARDS) on a new medicine called Traumakine. 

According to rtmagazine.com:

Scientists from University College London Hospitals (UCLH) completed a Phase II clinical trial for Faron Pharmaceuticals Ltd’s Traumakine, which demonstrated a significant reduction in mortality as a result of acute respiratory distress syndrome (ARDS), according to UCLH researchers.

The trial demonstrated an 81% reduction in mortality in ARDS patients, with a mortality of only 8.1% in patients treated with Traumakine, compared to the 32.2% mortality seen in the control group of ARDS patients, according to the study, which was published in The Lancet Respiratory Medicine.

The trial was conducted in eight intensive care units around the UK. It also found that other measured parameters, including length of mechanical ventilation needed, length of ICU stay, and support of vital functions also benefited from the Traumakine treatment.

That's pretty impressive results.

Reference:

1. "Promising Treatment for Acute Respiratory Distress Syndrome," rtmagazine.com, http://www.rtmagazine.com/2014/02/promising-treatment-acute-respiratory-distress-syndrome/, accessed on 2/18/14

RT Cave Facebook Page
RT Cave on Twitter